Evonik builds Vancouver GMP lipid facility
Analysis based on 12 articles · First reported Aug 27, 2026 · Last updated Aug 28, 2026
The investment signals Evonik's commitment to the growing lipid nanoparticle market, potentially boosting its competitive position in pharmaceutical delivery systems. Government funding reduces Evonik's capital expenditure burden, while the expansion may positively impact the Canadian life sciences sector and related supply chains.
Evonik Industries announced a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The investment exceeds 150 million CAD (93 million EUR), supported by up to 68 million CAD (42 million EUR) from the Canadian federal government's Strategic Response Fund. The facility will more than triple Evonik's manufacturing capacity for advanced pharmaceutical products, with production planned to begin by the end of 2029. The project strengthens Evonik's global lipid and LNP network, which spans Vancouver, Birmingham, Dossenheim, Hanau, Boston, and Lafayette. The LNP market is projected to reach US$2.7 billion by 2034. The expansion underscores Canada's leadership in life sciences and is expected to create highly skilled jobs in Canada — British Columbia.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard